Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$326K Hold
2,757
﹤0.01% 431
2026
Q1
$329K Hold
2,757
0.01% 422
2025
Q4
$375K Buy
2,757
+100
+4% +$14.4K 0.01% 398
2025
Q3
$392K Buy
2,657
+99
+4% +$13.7K 0.01% 397
2025
Q2
$331K Buy
+2,558
New +$310K 0.01% 417
2025
Q1
Sell
-1,857
Closed -$215K 498
2024
Q4
$215K Buy
1,857
+175
+10% +$22.1K ﹤0.01% 462
2024
Q3
$227K Hold
1,682
﹤0.01% 446
2024
Q2
$228K Hold
1,682
﹤0.01% 438
2024
Q1
$217K Buy
+1,682
New +$203K ﹤0.01% 449

Other funds holding XYL

Glenview Trust's XYL Position: Q2 2026 in Review

Glenview Trust held its Xylem (XYL) position steady in Q2 2026 at 2,757 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #431.

Glenview Trust first reported a position in XYL in Q1 2024 and has held it in 9 quarters since. The position peaked at $392K in Q3 2025. 1,098 funds tracked by Wall St. Rank hold XYL as of Q2 2026.

  • Glenview Trust held 2,757 shares of Xylem worth $326K as of Q2 2026.
  • Glenview Trust left its Xylem share count unchanged in Q2 2026.
  • Xylem made up ﹤0.01% of Glenview Trust's portfolio in Q2 2026, its #431 holding.
  • Glenview Trust first reported a position in Xylem in Q1 2024 and has held it in 9 quarters since.
  • Glenview Trust's Xylem position peaked at $392K in Q3 2025.
  • 1,098 funds tracked by Wall St. Rank held Xylem as of Q2 2026.

Based on Glenview Trust's 13F filing for Q2 2026, filed 11 Aug 2026.